>중동 및 아프리카 렌티바이러스 벡터 시장, 구성 요소별(렌티바이러스 프로모터, 렌티바이러스 퓨전 태그, 렌티바이러스 패키징 시스템, 기타), 유형(제품, 서비스), 세대(4세대, 3세대, 2세대, 1세대), 워크플로(상류 처리, 하류 처리), 전달 방법(체내, 체외), 질병 지표(암, 유전적 질환, 감염성 질환, 수의학적 질병, 기타), 응용 분야(유전자 치료, 백신학), 최종 사용자(생명공학 회사, 제약 회사, 계약 연구 기관, 계약 개발 및 제조 기관(CDMO), 학술/연구 기관), 국가(남아프리카, 사우디 아라비아, UAE, 이집트, 이스라엘 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 예측 2028
시장 분석 및 통찰력 : 중동 및 아프리카 렌티바이러스 벡터 시장
렌티바이러스 벡터 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 16.1%의 CAGR로 성장하고 있으며 2028년까지 2억 737만 달러에 도달할 것으로 예상한다고 분석했습니다. 렌티바이러스 벡터에 대한 수요 증가와 감염성 질환의 증가는 예측 기간 동안 시장 수요를 촉진한 주요 요인입니다.
렌티바이러스 벡터(LV)는 분열하지 않는 세포와 분열하는 세포에서 관심 유전자를 안정적으로 발현할 수 있는 능력 덕분에 포유류 세포 에서 유전자 전달을 위한 효율적인 매개체입니다 . 렌티바이러스는 긴 잠복기와 지속적인 감염이 있는 것으로 알려진 인간과 동물 병원체입니다. 초기 감염과 첫 증상이 나타나는 사이의 시간은 몇 개월 또는 몇 년에 이를 수 있습니다.
분자 생물학자들은 종종 바이러스 벡터를 사용하여 유전 물질을 세포로 전달합니다. 이 절차는 생체 내(살아있는 유기체 내부) 또는 세포 배양(시험관 내)에서 수행될 수 있습니다. 바이러스는 감염된 세포 내부로 유전체를 효율적으로 운반하기 위해 특수한 분자 메커니즘을 개발했습니다.
노령 인구의 증가와 이번 코로나19 사태 동안 백신 개발에 대한 수요는 렌티바이러스 벡터 시장의 성장에 효과적으로 도움이 됩니다. 그러나 확장성 부족과 렌티바이러스 벡터의 하류 정제 한계는 렌티바이러스 벡터 시장의 미래 성장을 방해할 수 있습니다. 주요 시장 참여자의 전략적 이니셔티브와 유전체학에 대한 자금 지원 증가는 아시아 태평양 렌티바이러스 벡터 시장 성장의 기회로 작용합니다. 렌티바이러스 벡터 제품과 관련된 엄격한 규제 정책과 부작용은 미래 시장 성장에 대한 과제로 작용합니다.
렌티바이러스 벡터 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
중동 및 아프리카 렌티바이러스 벡터 시장 범위 및 시장 규모
렌티바이러스 벡터 시장은 구성 요소, 유형, 세대, 워크플로, 전달 방법, 질병 표시, 응용 프로그램 및 최종 사용자를 기준으로 하는 8개의 주요 세그먼트로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 구성 요소를 기준으로 렌티바이러스 벡터 시장은 렌티바이러스 프로모터, 렌티바이러스 퓨전 태그, 렌티바이러스 패키징 시스템 및 기타로 세분화됩니다. 2021년에는 의료비 지출 증가로 인해 렌티바이러스 패키징 시스템 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 유형에 따라 렌티바이러스 벡터 시장은 제품과 서비스로 세분화됩니다. 2021년에는 유전 질환의 높은 발병률로 인해 제품 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 렌티바이러스 벡터 시장은 세대별로 4세대, 3세대, 2세대, 1세대로 구분됩니다. 2021년에는 활발한 연구 개발 활동으로 인해 4세대 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 워크플로우를 기준으로 렌티바이러스 벡터 시장은 상류 처리 와 하류 처리로 구분됩니다. 2021년에는 기술 발전으로 인해 상류 처리 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 전달 방식을 기준으로 렌티바이러스 벡터 시장은 생체 내와 생체 외로 세분화됩니다. 2021년에는 생체 내 세그먼트가 더 나은 효율성으로 인해 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 질병 표시에 따라 렌티바이러스 벡터 시장은 암, 유전적 질환, 감염성 질환 , 수의학적 질병 및 기타로 세분화됩니다. 2021년에는 중동 및 아프리카 지역에서 노인 및 암 사례가 증가함에 따라 암 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- 응용 분야별로 렌티바이러스 벡터 시장은 유전자 치료 와 백신 치료로 구분됩니다. 2021년에는 유전자 치료에 대한 인지도가 높아지고 임상 시험 승인이 증가함에 따라 유전자 치료 부문이 렌티바이러스 벡터 시장을 지배할 것으로 예상됩니다.
- On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to rising government funds for gene therapy research and development department.
Lentiviral Vector Market Country Level Analysis
The lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.
The countries covered in the lentiviral vector market report are the Saudi Arabia, South Africa, UAE, Israel, Egypt, rest of Middle East and Africa.
Upstream processing segment in Middle East and Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of rising investments for research activities. South Africa is leading the growth of the Middle East and Africa market and up-stream processing segment is dominating in this region due to rising funding by government for technological improvements in R & D activities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Lentiviral Vector Market
Lentiviral vector market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in lentiviral vector sales, partnership, acquisition, distribution agreement among the market players of Asia-Pacific region. The data is available for historic period 2010 to 2019.
Competitive Landscape and Lentiviral Vector Market Share Analysis
렌티바이러스 벡터 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 있습니다. 위에 제공된 데이터 포인트는 렌티바이러스 벡터 시장과 관련된 회사의 초점에만 관련이 있습니다.
렌티바이러스 벡터 시장 보고서를 다루는 주요 기업으로는 Merck KGaA, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, System Biosciences, LLC, Takara Bio Inc., OriGene Technologies, Inc., Sino Biological, Inc., Lonza 등이 있으며, 국내 기업도 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 계약과 협정을 체결하면서 렌티바이러스 벡터 시장도 가속화되고 있습니다.
예를 들어,
- 2021년 2월, Thermo Fisher Scientific Inc.는 연례 CMO Leadership Awards에서 6개의 상을 수상했다고 발표했습니다. Life Science Leader와 Outsourced Pharma가 수여하는 상은 바이오제약 및 바이오테크 회사에서 평가한 최고의 계약 제조 파트너를 인정합니다. 이러한 인정을 통해 전 세계적으로 입지를 강화하고 향후 몇 년 동안 성장이 급증할 것으로 예상됩니다.
시장 참여자들의 협업, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 기타 전략을 통해 렌티바이러스 벡터 시장에서 회사의 입지를 강화하고 있으며, 이는 조직의 수익 성장에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 COMPONENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ADHERENT AND SUSPENSION CULTURES: OVERVIEW
4.2 PRICING OF LENTIVIRAL VECTORS: PRODUCT AND SERVICE
4.2.1 PRODUCT
4.2.2 SERVICES
5 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: REGULATORY FRAMEWORK
5.1 REGULATION IN THE UNITED STATES
5.2 REGULATIONS IN EUROPE
5.3 REGULATIONS IN INDIA
5.4 REGULATIONS IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN DEMAND FOR VIRAL VECTORS
6.1.2 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT
6.1.3 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY
6.1.4 RISE IN NUMBER OF INFECTIOUS DISEASES
6.1.5 GROWING GERIATRIC POPULATION
6.2 RESTRAINTS
6.2.1 LACK OF SCALABILITY
6.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION
6.2.3 SHORTAGE OF SKILLED PERSONNELS
6.3 OPPORTUNITIES
6.3.1 INCREASED HEALTHCARE FACILITY AND FUNDING FOR GENOMICS
6.3.2 RISE IN TECHNOLOGICAL ADVANCEMENT
6.3.3 INCREASE IN DEMAND FOR PERSONALIZED MEDICINES
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT APPROVAL POLICIES
6.4.2 SIDE-EFFECTS ASSOCIATED WITH LENTIVIRAL VECTORS INTEGRATION
7 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
7.5 CONCLUSION
8 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT
8.1 OVERVIEW
8.2 LENTIVIRUS PACKAGING SYSTEMS
8.3 LENTIVIRAL PROMOTER
8.3.1 LENTIVIRUS PROMOTER VECTORS
8.3.2 LENTIVIRUS PROMOTERLESS VECTORS
8.4 LENTIVIRAL FUSION TAGS
8.5 OTHERS
9 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE
9.1 OVERVIEW
9.2 PRODUCT
9.2.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)
9.2.2 FELINE IMMUNODEFICIENCY VIRUS (FIV)
9.2.3 EQUINE INFECTIOUS ANEMIA VIRUS (EIAV)
9.3 SERVICES
10 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION
10.1 OVERVIEW
10.2 4TH GENERATION
10.3 3RD GENERATION
10.4 2ND GENERATION
10.5 1ST GENERATION
11 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW
11.1 OVERVIEW
11.2 UPSTREAM PROCESSING
11.2.1 VECTOR AMPLIFICATION & EXPANSION
11.2.2 VECTOR RECOVERY/ HARVESTING
11.3 DOWNSTREAM PROCESSING
11.3.1 PURIFICATION
11.3.2 FILL-FINISH
12 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD
12.1 OVERVIEW
12.2 IN-VIVO
12.3 EX-VIVO
13 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION
13.1 OVERVIEW
13.2 CANCER
13.3 GENETIC DISORDERS
13.3.1 B-THALESSEMIA
13.3.2 X-LINKED ADRENO LEUKODYSTROPHY
13.3.3 METACHROMATIC LEUKODYSTROPHY
13.3.4 WISKOTT-ALDRICH SYNDROME
13.3.5 OTHERS
13.4 INFECTIOUS DISEASES
13.4.1 HIV
13.4.2 OTHERS
13.5 VETERINARY DISEASES
13.6 OTHERS
14 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 GENE THERAPY
14.2.1 RECOMBINANT PROTEIN EXPRESSION
14.2.2 FUNCTIONAL ASSAYS
14.2.3 IN VITRO TRANSCRIPTION
14.2.4 PROTEIN CHARACTERIZATION
14.2.5 OTHERS
14.3 VACCINOLOGY
15 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER
15.1 OVERVIEW
15.2 ACADEMIC/ RESEARCH INSTITUTES
15.3 PHARMACEUTICAL COMPANIES
15.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS
15.5 BIOTECHNOLOGY COMPANIES
15.6 CONTRACT RESEARCH ORGANIZATIONS
16 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 SAUDI ARABIA
16.1.3 U.A.E.
16.1.4 EGYPT
16.1.5 ISRAEL
16.1.6 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT
19 COMPANY PROFILE
19.1 OXFORD BIOMEDICA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 THERMO FISHER SCIENTIFIC INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 MERCK KGAA
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 LONZA
19.4.1 COMPANY SNAPSHOT
19.4.2 RECENT ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 CYTIVA (A SUBSIDIARY OF DANAHER)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 APPLIED BIOLOGICAL MATERIALS INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BATAVIA BIOSCIENCES B.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEBIRD BIO, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 CELL BIOLABS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CREATIVE BIOLABS
19.10.1 COMPANY SNAPSHOT
19.10.2 SERVICE PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 COBRA BIOLOGICS LIMITED
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 FINVECTOR OY
19.12.1 COMPANY SNAPSHOT
19.12.2 SERVICE PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 FUJIFIM DIOSYNTH BIOTECHNOLOGIES (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
19.13.1 COMPANY SNAPSHOT
19.13.2 RECENT ANALYSIS
19.13.3 SERVICE PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 GENEMEDI
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ORIGENE TECHNOLOGIES, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 SINO BIOLOGICAL, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SIRION-BIOTECH GMBH
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 SYSTEM BIOSCIENCES, LLC
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 TAKARA BIO INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 RECENT ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 WAISMAN BIOMANUFACTURING
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
TABLE 1 THERMO FISHER SCIENTIFIC
TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN
TABLE 3 KERAFAST
TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.
TABLE 5 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 U.A.E. LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 93 U.A.E. LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 94 U.A.E. LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 U.A.E. PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 U.A.E. LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 97 U.A.E. LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 98 U.A.E. UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 99 U.A.E. DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 100 U.A.E. LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 101 U.A.E. LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 102 U.A.E. GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 103 U.A.E. INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 104 U.A.E. LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 105 U.A.E. GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 106 U.A.E. LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 107 EGYPT LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 108 EGYPT LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 109 EGYPT LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 EGYPT PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 EGYPT LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 112 EGYPT LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 113 EGYPT UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 114 EGYPT DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 115 EGYPT LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 116 EGYPT LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 117 EGYPT GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 118 EGYPT INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 119 EGYPT LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 120 EGYPT GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 121 EGYPT LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)
TABLE 127 ISRAEL LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)
TABLE 128 ISRAEL UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 129 ISRAEL DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)
TABLE 130 ISRAEL LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)
TABLE 131 ISRAEL LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)
TABLE 132 ISRAEL GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 133 ISRAEL INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)
TABLE 134 ISRAEL LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 ISRAEL GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 136 ISRAEL LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 REST OF MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: SEGMENTATION
FIGURE 12 GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 LENTIVIRUS PACKAGING SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET
FIGURE 15 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2020
FIGURE 16 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2019-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, 2020
FIGURE 24 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, 2019-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY GENERATION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2020
FIGURE 28 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2019-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY WORK FLOW, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2020
FIGURE 32 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2019-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2020
FIGURE 36 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2019-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2020
FIGURE 40 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2019-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, 2020
FIGURE 44 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 45 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, CAGR (2021-2028)
FIGURE 46 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: SNAPSHOT (2020)
FIGURE 48 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020)
FIGURE 49 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: BY COMPONENT (2021-2028)
FIGURE 52 MIDDLE EAST AND AFRICA LENTIVIRAL VECTOR MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.